Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 26, 2020
Daily News
March 26, 2020
- COVID-19-Disrupted Air Freight Hitting Commodity Transports, but No Major Impact So Far on Drugs
March 26, 2020
- MHLW to Make Pediatric Medical Database Available to Researchers on Trial Basis
March 26, 2020
- Fujifilm Launches Contract Services for Process Development, Manufacturing of Liposome Formulations
March 26, 2020
- Asahi Kasei’s US Subsidiary Turbocharges Ventilator Production amid Coronavirus Outbreak
March 26, 2020
- Face Mask Shortages Crippling Drug Makers’ Business Activities, Travel Restrictions Could Delay Approval
March 26, 2020
- Aspen Japan President to Lead Sandoz K.K.
March 26, 2020
- OxyContin’s Chronic Pain Nod Delayed as Distribution System Not Ready
March 26, 2020
- Japan OKs Enhertu, 3 Sakigake Drugs, Beovu, Latuda, and More
March 26, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…